Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
April 03 2024 - 7:30AM
Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative
medicine company focused on the development, manufacture, and
commercialization of product solutions for the Advanced Wound Care
and Surgical & Sports Medicine markets, today announced that on
March 29, 2024, the United States District Court for the Eastern
District of New York granted, with prejudice, the Company’s motion
to dismiss all claims asserted.
“We are very pleased with the Court's decision,” said Lori
Freedman, Chief Administrative and Legal Officer for Organogenesis.
“We are happy to have this behind us so we can continue to focus on
our mission to substantially improve patient outcomes while
lowering the overall cost of care.”
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine
company focused on the development, manufacture and
commercialization of solutions for the advanced wound care and
surgical and sports medicine markets. Organogenesis offers a
comprehensive portfolio of innovative regenerative products to
address patient needs across the continuum of care. For more
information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Organogenesis (NASDAQ:ORGO)
Historical Stock Chart
From Jul 2023 to Jul 2024